Femasys inc. regains compliance with nasdaq listing requirements

Atlanta, oct. 11, 2023 (globe newswire) -- femasys inc. (nasdaq: femy), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative diagnostic products, today announced that it has it has received notice from the nasdaq stock market llc (nasdaq) informing femasys that it has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550(a)(2) for continued listing on the nasdaq capital market. consequently, femasys is now in compliance with all applicable listing standards, and its common stock will continue to be listed on the nasdaq capital market.
FEMY Ratings Summary
FEMY Quant Ranking